Topical treatment and combination approaches for vitiligo: new insights, new developments
- PMID: 20197746
Topical treatment and combination approaches for vitiligo: new insights, new developments
Abstract
Despite much research done involving elucidation of the pathogenesis of vitiligo, a precise cause is still not known. Prevalent hypotheses include the autoimmune, genetic, neural, self-destruction, growth factor deficiency, viral, and convergence theories, which have served as the basis for treatment formulation. Topical therapies have been a mainstay of vitiligo treatment, with or without phototherapy. Topical treatments used in the treatment of vitiligo include steroids, calcineurin inhibitors, vitamin D analogues, pseudocatalase, and depigmenting agents. Combination therapies are used to improve the success rate of repigmentation. In this article, we have examined randomized controlled trials utilizing topical treatments used as monotherapy or combination therapy. Although psoralen and khellin can be used as topical agents, used in conjunction with UV radiation, we have not included them in the review due to their inability to be used as monotherapy. We have also excluded less used or ineffective topical agents, such as melagenina, topical phenylalanine, topical L-DOPA, coal tar, anacarcin forte oil and topical minoxidil. According to current guidelines, a less than two month trial of potent or very potent topical corticosteroids or topical calcineurin inhibitors may be used for therapy of localized vitiligo (<20% skin surface area). Combinations of topical corticosteroids with excimer laser and UVA seem to be more effective than steroids alone. Pseudocatalase plus NB-UVB does not seem to be more effective than placebo with NB-UVB. Combinations of vitamin D analogues have varied efficacy based on which type is used and the type of UV light. Efficacy of calcineurin inhibitor combinations also vary based on the type used and UV light combined, with tacrolimus being more effective with excimer laser. Pimecrolimus has been effective with NB-UVB and excimer laser on facial lesions, and microdermabrasion on localized areas.
Similar articles
-
Treatment of vitiligo: advantages and disadvantages, indications for use and outcomes.G Ital Dermatol Venereol. 2011 Oct;146(5):373-95. G Ital Dermatol Venereol. 2011. PMID: 21956273
-
An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.Eur J Dermatol. 2009 Nov-Dec;19(6):588-93. doi: 10.1684/ejd.2009.0779. Epub 2009 Aug 4. Eur J Dermatol. 2009. PMID: 19651562 Clinical Trial.
-
A review of monochromatic excimer light in vitiligo.Br J Dermatol. 2012 Sep;167(3):468-78. doi: 10.1111/j.1365-2133.2012.11008.x. Epub 2012 Aug 8. Br J Dermatol. 2012. PMID: 22524428 Review.
-
Efficacy of topical calcineurin inhibitors in vitiligo.Int J Dermatol. 2013 Apr;52(4):491-6. doi: 10.1111/j.1365-4632.2012.05697.x. Epub 2013 Jan 20. Int J Dermatol. 2013. PMID: 23331250 Review.
-
Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.Photodermatol Photoimmunol Photomed. 2017 Jan;33(1):22-31. doi: 10.1111/phpp.12277. Epub 2016 Nov 23. Photodermatol Photoimmunol Photomed. 2017. PMID: 27696531 Review.
Cited by
-
Treatment of segmental vitiligo with normal-hair follicle autograft.Med J Islam Repub Iran. 2013 Nov;27(4):210-4. Med J Islam Repub Iran. 2013. PMID: 24926182 Free PMC article.
-
[Treatment of vitiligo].Hautarzt. 2016 Mar;67(3):249-64. doi: 10.1007/s00105-016-3768-4. Hautarzt. 2016. PMID: 26909811 German.
-
HPMC-Zein Film-forming Gel Loaded with 5-Fluorouracil Coupled with CO2 Laser Dermabrasion for Managing Stable Vitiligo.AAPS PharmSciTech. 2024 Sep 26;25(7):225. doi: 10.1208/s12249-024-02937-0. AAPS PharmSciTech. 2024. PMID: 39327349
-
Mutant HSP70 reverses autoimmune depigmentation in vitiligo.Sci Transl Med. 2013 Feb 27;5(174):174ra28. doi: 10.1126/scitranslmed.3005127. Sci Transl Med. 2013. PMID: 23447019 Free PMC article.
-
Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response.Front Immunol. 2021 Mar 5;12:613031. doi: 10.3389/fimmu.2021.613031. eCollection 2021. Front Immunol. 2021. PMID: 33815367 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical